SEC registrant · CIK 0001321834

Q/C TECHNOLOGIES, INC. (QCLS)

Q/C TECHNOLOGIES, INC. (CIK 0001321834, ticker QCLS) reported revenue of $1.58 million ($1,577,033) for FY2019 (2019-01-01 to 2019-12-31) and net income of -$11.63 million (-$11,627,122) for FY2025 (2025-01-01 to 2025-12-31), as filed in its 10-K filed 2020-03-25 (accession 0001493152-20-004650) and its 10-K filed 2026-04-15 (accession 0001493152-26-016872).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001321834
TickersQCLS (Nasdaq)
EINnot in EDGAR (or not a valid EIN)
SIC industry code2835 In Vitro & In Vivo Diagnostic Substances
State or country of incorporationDE
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_5sngwjjc838hcw80j8bf673vt0
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$1,577,033FY20192019-01-01 to 2019-12-3110-K2020-03-250001493152-20-004650RevenueFromContractWithCustomerExcludingAssessedTax
Net income-$11,627,122FY20252025-01-01 to 2025-12-3110-K2026-04-150001493152-26-016872NetIncomeLoss
Total assets$41,166,096FY2025as of 2025-12-3110-K2026-04-150001493152-26-016872Assets
Total liabilities$16,441,042FY2025as of 2025-12-3110-K2026-04-150001493152-26-016872Liabilities
Stockholders' equity$21,751,675FY2025as of 2025-12-3110-K2026-04-150001493152-26-016872StockholdersEquity
Operating cash flow-$9,065,619FY20252025-01-01 to 2025-12-3110-K2026-04-150001493152-26-016872NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$8.66 per shareFY20252025-01-01 to 2025-12-3110-K2026-04-150001493152-26-016872EarningsPerShareDiluted
Shares outstanding7,853,429 sharesFY2025as of 2026-04-1210-K2026-04-150001493152-26-016872EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2016-2025, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20192019-01-01 to 2019-12-31$1,577,03310-K2020-03-250001493152-20-004650
RevenueFY20182018-01-01 to 2018-12-31$1,665,57010-K2020-03-250001493152-20-004650
RevenueFY20172017-01-01 to 2017-12-31$3,354,71210-K/A2018-07-130001493152-18-009979
RevenueFY20162016-01-01 to 2016-12-31$2,960,91210-K/A2018-07-130001493152-18-009979
Net incomeFY20252025-01-01 to 2025-12-31-$11,627,12210-K2026-04-150001493152-26-016872
Net incomeFY20242024-01-01 to 2024-12-31-$23,359,33410-K2026-04-150001493152-26-016872
Net incomeFY20232023-01-01 to 2023-12-31-$3,999,95010-K2025-04-110001641172-25-003814
Net incomeFY20222022-01-01 to 2022-12-31-$15,197,33610-K2024-04-010001493152-24-012533
Net incomeFY20212021-01-01 to 2021-12-31-$29,889,04510-K2023-03-310001493152-23-010384
Net incomeFY20202020-01-01 to 2020-12-31-$9,487,82410-K2022-03-310001493152-22-008546
Net incomeFY20192019-01-01 to 2019-12-31-$3,888,24910-K2021-03-010001493152-21-005129
Net incomeFY20182018-01-01 to 2018-12-31-$10,849,03410-K2020-03-250001493152-20-004650
Net incomeFY20172017-01-01 to 2017-12-31-$7,366,31010-K2019-04-010001493152-19-004590
Net incomeFY20162016-01-01 to 2016-12-31-$3,303,53810-K/A2018-07-130001493152-18-009979
  • Revenue for FY2017 was restated: first reported as $3,929,527 (accession 0001493152-18-004626, filed 2018-04-03).
  • Net income for FY2020 was restated: first reported as -$17,580,609 (accession 0001493152-21-005129, filed 2021-03-01).
  • Net income for FY2017 was restated: first reported as -$5,805,326 (accession 0001493152-18-004626, filed 2018-04-03).

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2026-08-122026-06-300001493152-26-037333form10-q.htm
10-Q2026-05-152026-03-310001493152-26-023751form10-q.htm
10-K/A2026-04-292025-12-310001493152-26-019663form10-ka.htm
10-K2026-04-152025-12-310001493152-26-016872form10-k.htm
10-Q2025-11-192025-09-300001493152-25-024320form10-q.htm
10-Q2025-08-192025-06-300001641172-25-024859form10-q.htm
10-Q2025-05-152025-03-310001641172-25-010937form10-q.htm
10-K2025-04-112024-12-310001641172-25-003814form10-k.htm
10-Q2024-11-142024-09-300001493152-24-046026form10-q.htm
10-Q2024-08-192024-06-300001493152-24-032940form10-q.htm
10-Q2024-05-152024-03-310001493152-24-019976form10-q.htm
10-K2024-04-012023-12-310001493152-24-012533form10-k.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001321834published by the sourcedata.sec.gov/submissions/CIK0001321834.json2026-10-21

Former names

NameFromTo
Q/C TECHNOLOGIES, INC.2025-08-052026-10-02
TNF Pharmaceuticals, Inc.2024-06-272025-09-10
MyMD Pharmaceuticals, Inc.2021-04-162024-07-01
Akers Biosciences, Inc.2017-04-132021-04-16
Akers Biosciences Inc2005-03-232017-04-11

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001321834.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001321834.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001321834" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001321834/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001321834/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1321834"}

On SEC EDGAR

About this data